RGEN - Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors | Benzinga
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.
Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023.
The company recently entered the single-use mixing market with the launch of its MixOne platform, leveraging the success of its existing stainless steel (repeat-use) product line.
Metenova is expected to contribute approximately $5 million in revenue to Repligen in Q4 of 2023 and $25 million-$27 million in 2024, with 20%-25% revenue growth in 2025 forward.
The acquisition is anticipated to be accretive to Repligen's adjusted gross and operating margins in 2024 and to be accretive to adjusted EPS in 2025.
The transaction is expected to be completed ...